Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for Supine Hypertension in Neurogenic Orthostatic Hypotension
NCT02963181Phase 1Terminated
- Start
- Mar 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of melatonin in Supine hypertension (SH) (2 arms). Primary endpoints: Investigation into the integrity of post-ganglionic sympathetic nerves and Effects of melatonin on supine hypertension at 4 weeks. Started Mar 2018; status: terminated.
02
Drugs
melatonin
03
Conditions
Supine hypertension (SH)
Beyond the preview
Go deeper on NCT02963181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963181.